P.A.W. Capital Corp Chemo Centryx, Inc. Transaction History

P.A.W. Capital Corp

$44.3 Million
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2019 Oct 30, 2019	SELL	$6.47 - $8.96 $388,200 - $537,600	-60,000 Closed	0 $0
Q2 2019 Jul 31, 2019	BUY	$8.31 - $14.85 $498,600 - $891,000	60,000 New	60,000 $558,000
Q1 2019 Apr 17, 2019	SELL	$10.01 - $13.89 $500,500 - $694,500	-50,000 Closed	0 $0
Q4 2018 Feb 06, 2019	SELL	$9.15 - $12.26 $366,000 - $490,400	-40,000 Reduced 44.44%	50,000 $546,000
Q3 2018 Oct 24, 2018	BUY	$10.49 - $13.72 $52,450 - $68,600	5,000 Added 5.88%	90,000 $1.14 Million
Q2 2018 Jul 25, 2018	BUY	$10.62 - $13.98 $106,199 - $139,800	10,000 Added 13.33%	85,000 $1.12 Million
Q1 2018 Apr 26, 2018	SELL	$5.9 - $14.99 $501,500 - $1.27 Million	-85,000 Reduced 53.13%	75,000 $1.02 Million
Q3 2017 Oct 23, 2017	BUY	$6.5 - $10.69 $1.04 Million - $1.71 Million	160,000	160,000 $1.19 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of P.A.W. Capital Corp, based on Form 13F filings with the SEC.

News

Stay updated on P.A.W. Capital Corp with notifications on news.